Al­ny­lam preps for an­oth­er PhI­II RNAi study, ‘break­through’ sta­tus in hand

Tout­ing ear­ly-stage ev­i­dence that its RNAi drug for rare cas­es of acute he­pat­ic por­phyr­ia had be­gun to demon­strate its promise in the clin­ic, Al­ny­lam to­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.